138 related articles for article (PubMed ID: 26410247)
1. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
Lexchin J
Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
[TBL] [Abstract][Full Text] [Related]
2. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
Lexchin J
Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
[TBL] [Abstract][Full Text] [Related]
3. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
5. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
Lexchin J
CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
[TBL] [Abstract][Full Text] [Related]
6. Association between FDA black box warnings and Medicare formulary coverage changes.
Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
[TBL] [Abstract][Full Text] [Related]
7. Ontario's formulary committee: how recommendations are made.
PausJenssen AM; Singer PA; Detsky AS
Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
[TBL] [Abstract][Full Text] [Related]
8. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
Lexchin J
BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
[TBL] [Abstract][Full Text] [Related]
9. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
10. How complete are drug history profiles that are based on public drug benefit claims?
Paterson JM; Suleiman A; Hux JE; Bell C
Can J Clin Pharmacol; 2008; 15(1):e108-16. PubMed ID: 18283220
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade.
Penedones A; Mendes D; Alves C; Marques FB
J Ocul Pharmacol Ther; 2015 Jun; 31(5):258-68. PubMed ID: 25871404
[TBL] [Abstract][Full Text] [Related]
12. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.
Grootendorst P; Shim M; Falconi A; Robinson T; Lexchin J
Int J Health Serv; 2018 Oct; 48(4):702-715. PubMed ID: 30040005
[TBL] [Abstract][Full Text] [Related]
13. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
[TBL] [Abstract][Full Text] [Related]
14. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
Lexchin J
Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
[TBL] [Abstract][Full Text] [Related]
15. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
16. Formulary decisions for pre-1938 medications.
Culley CM; Carroll BA; Skledar SJ
Am J Health Syst Pharm; 2008 Jul; 65(14):1363-7. PubMed ID: 18593683
[TBL] [Abstract][Full Text] [Related]
17. Drug policy: making effective drugs available without bankrupting the healthcare system.
Laupacis A; Anderson G; O'Brien B
Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
[TBL] [Abstract][Full Text] [Related]
18. New and incremental FDA black box warnings from 2008 to 2015.
Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
[TBL] [Abstract][Full Text] [Related]
19. Potentially inappropriate prescribing in Canada relative to the US.
Rochon PA; Lane CJ; Bronskill SE; Sykora K; Anderson GM; Mamdani MM; Gurwitz JH; Dhalla IA
Drugs Aging; 2004; 21(14):939-47. PubMed ID: 15554752
[TBL] [Abstract][Full Text] [Related]
20. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
